|
|
The Competitive Landscape of Cancer Gene Therapy (2nd issue)Published by: BioSeeker Group AB Published: May. 13, 2002 - 284 Pages Table of ContentsIntroduction
AbstractCancer is not one single disease but can be divided into almost 200 different diseases. In the United States, overall annual costs associated with cancer currently amount to $107 billion and the worldwide anti-cancer market, valued at more than $15 billion in 1998, is projected to nearly double by 2003. Based on advances in cell and molecular biology, the number of therapeutic cancer targets in pipeline is rapidly increasing. Numerous long-standing pharma companies as well as young biotechnology firms are driving cancer research today and the future.'The Competitive Landscape of Cancer Gene Therapy ' provides a complete and thorough description of the current cancer gene therapy pipelines. Further, it provides contact data, financial information, partnership activities, and descriptions about products in the pipeline for 44 companies active in the cancer field. A short description is also provided for 21 companies with close contact with the cancer gene therapy market. The report includes 125 companies with interest in the field, 148 pipeline therapies and 215 alliances. We also present a description and analysis of areas of development, trends, collaborations, indications, and clinical trial progress for the overall market. The report starts with a extensive section describing and analysing the gene delivery technologies. The report is a comprehensive information platform focusing on the latest developments in the field of cancer gene therapy. To assist you in grasping the material in the report we have generated 32 different tables and figures. Includes also extensive and descriptive figures of collaboration clusters. The report starts with a section that disecting different gene delivery systems and related companies. The conclusive section provides BioSeeker Group's comments and analysis on this material. Companies included: AlphaVax, ALZA Corp, AMDL Inc, Ark Therapeutics Ltd, Austrian Nordic Biotherapeutics AG, AVAX Technologies, Aventis RPR Gencell, Avigen Inc, Bavarian Nordic, Biogen, Biovector Therapeutics SA, BioVex, Calydon Inc, Cantab Pharmaceuticals, Cell Genesys, Chiron, Copernicus Therapeutics Inc, Cytogen, Genetix Pharmaceuticals Inc, Genetronics Inc, GenEra S.p.A, Genopoietic, Genotherapeutics Inc, GenStar Therapeutics, GenVec Inc, Genzyme Molecular Oncology Corp, Got-A-Gene AB, G.O.T. GmbH & Co. KG, Imgenex Corporation, Introgen Therapeutics Inc, ML Laboratories (Cobra Therapeutics), MainGen Biotechnologie, Mologen Holding AG, Northwest Biotherapeutics, Oxford BioMedica plc, ONYX Pharma, Oxxon Pharmaccines Ltd, Progenics Pharma, Schering (Canij), Supratek Pharma Inc, Targeted Genetics Corp, Therion Biologics, Titan Pharmaceuticals, Transgene, Valentis, Vical Inc. |
|
|||
|
About MarketResearch.com
|
||||